SPRY Logo

ARS Pharmaceuticals, Inc. (SPRY) 

NASDAQ$11.42
Market Cap
$1.11B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
41 of 953
Rank in Industry
33 of 545

SPRY Stock Price History Chart

SPRY Stock Performance

7 days+2.98%+0.98%-1.14%
1 month-4.2%-3.02%-2.65%
6 months+0.61%-7.58%+7.33%
1 year+48.25%-2.21%+19.01%

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$13,289,41033
Sells
$94,289,5609597

Related Transactions

RA CAPITAL MANAGEMENT, L.P.90$398.68M0$0$398.68M
Scott Kathleen D.Chief Financial Officer0$02$400,000$-400,000
Karas EricChief Commercial Officer0$04$420,423$-420,423
Dorsey BrianChief Operating Officer0$04$1.63M$-1.63M
Shawver Lauradirector0$04$3.24M$-3.24M
Chakma JustinChief Business Officer0$011$7.09M$-7.09M
Lowenthal Richard EPRESIDENT AND CEO0$030$23.09M$-23.09M
Tanimoto SarinaCHIEF MEDICAL OFFICER0$030$23.09M$-23.09M
Thompson Peter A.director0$024$75.52M$-75.52M
Flynn James E10 percent owner0$076$385.46M$-385.46M
ORBIMED ADVISORS LLCdirector0$0168$528.61M$-528.61M

About ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

Insider Activity of ARS Pharmaceuticals, Inc.

Over the last 12 months, insiders at ARS Pharmaceuticals, Inc. have bought $13.29M and sold $94.29M worth of ARS Pharmaceuticals, Inc. stock.

On average, over the past 5 years, insiders at ARS Pharmaceuticals, Inc. have bought $25.62M and sold $32.63M worth of stock each year.

Highest buying activity among insiders over the last 12 months: RA CAPITAL MANAGEMENT, L.P. () — $398.68M.

The last purchase of 505,954 shares for transaction amount of $4.95M was made by RA CAPITAL MANAGEMENT, L.P. () on 2024‑03‑27.

List of Insider Buy and Sell Transactions, ARS Pharmaceuticals, Inc.

2025-01-06SaleShawver Lauradirector
50,000
0.0511%
$11.10$555,065+2.35%
2024-12-17SaleTanimoto SarinaCHIEF MEDICAL OFFICER
100,000
0.1035%
$11.67$1.17M-5.48%
2024-12-17SaleLowenthal Richard EPRESIDENT AND CEO
100,000
0.1035%
$11.67$1.17M-5.48%
2024-12-13SaleChakma JustinChief Business Officer
27,272
0.0282%
$12.06$328,969-6.18%
2024-12-12SaleChakma JustinChief Business Officer
117,333
0.1186%
$12.27$1.44M-11.55%
2024-12-12SaleDorsey BrianChief Operating Officer
25,000
0.0253%
$12.30$307,433-11.55%
2024-12-11SaleDorsey BrianChief Operating Officer
15,000
0.0154%
$12.43$186,426-8.84%
2024-12-10SaleTanimoto SarinaCHIEF MEDICAL OFFICER
100,000
0.1038%
$13.16$1.32M-13.59%
2024-12-10SaleLowenthal Richard EPRESIDENT AND CEO
100,000
0.1038%
$13.16$1.32M-13.59%
2024-12-10SaleChakma JustinChief Business Officer
50,000
0.0519%
$13.15$657,625-13.59%
2024-12-06SaleChakma JustinChief Business Officer
50,000
0.0517%
$14.23$711,615-20.11%
2024-12-05SaleChakma JustinChief Business Officer
49,640
0.0521%
$14.13$701,642-19.50%
2024-12-04SaleShawver Lauradirector
14,772
0.0146%
$13.75$203,109-21.36%
2024-12-04SaleChakma JustinChief Business Officer
45,000
0.0452%
$13.95$627,944-21.36%
2024-12-04SaleKaras EricChief Commercial Officer
6,283
0.0063%
$14.00$87,962-21.36%
2024-12-03SaleShawver Lauradirector
87,984
0.0888%
$13.26$1.17M-15.14%
2024-12-03SaleChakma JustinChief Business Officer
45,000
0.0452%
$13.19$593,402-15.14%
2024-12-02SaleShawver Lauradirector
97,244
0.1019%
$13.56$1.32M-11.71%
2024-12-02SaleChakma JustinChief Business Officer
45,000
0.0475%
$13.67$615,218-11.71%
2024-12-02SaleKaras EricChief Commercial Officer
3,717
0.0041%
$14.11$52,461-11.71%
Total: 118
*Gray background shows transactions not older than one year

Insider Historical Profitability

132.88%
RA CAPITAL MANAGEMENT, L.P.
9958073
10.2465%
$11.4250+131.88%
ORBIMED ADVISORS LLCdirector
0
0%
$11.4214
Thompson Peter A.director
0
0%
$11.4214
Fitzpatrick Alexander AChief Legal Officer
89227
0.0918%
$11.4220+133.38%
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$9,548,561
115
42.68%
$1.36B
$42,566,043
62
20.68%
$1.27B
$1,100,323,459
57
37.65%
$1.38B
$30,734,139
42
4.73%
$1.27B
$89,002,190
39
17.92%
$991.52M

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders

Institutional Investor Ownership Vs Market, Sector, Industry for Q1 1970

Financial Ratios

Summary
Comparison with Competitors
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Investor OwnershipSellsBuys